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The optimum glucocorticoid preparation, total daily dose, and dose schedule for the treatment of congenital adrenal hyperplasia remain controversial.' Hydrocortisone is probably the preparation of choice in infancy and childhood, but in adolescents near completion of growth and adults dexamethasone may be a convenient alternative. [1] [2] [3] The potency of dexamethasone in relation to both pituitary-adrenal suppression and side effects is much greater.
Patients
Ten patients (three males and seven females) aged 12-29 years with 21-hydroxylase deficiency (classic salt losing type) congenital adrenal hyperplasia took part in the study.
Patients had been previously treated with multiple daily doses of hydrocortisone and were changed to dexamethasone when growth was complete or because there was difficulty in achieving adequate control (this was found mainly in postmenarchal girls in whom menses were irregular). Each patient had an adult bone age.
Profiles of 170H-progesterone concentrations in blood spot and saliva samples collected at 0800, 1200, 1800, 2200 hours on two consecutive days, and a single measurement of plasma testosterone concentration at 0900 hours (females only), were used to assess the degree of therapeutic control immediately before starting dexamethasone, 10 [tg/kg/day. The total amount was given orally at 0900 for one month, at 2100 hours for one month, and in equally divided doses at 0900 and 2100 hours during the third month of the study. The steroid profiles were repeated at the end of each one month period and the results compared with previously published reference values for adequacy of control. 4 Capsules containing 100 [ig of dexamethasone were used to achieve accurate dosage. Patients thereafter reverted to a single morning dose of dexamethasone with the total daily dose adjusted according to the results of regular steroid profiles determined during the ensuing year.
Results
The degree of therapeutic control achieved during each treatment regimen is shown in the The degree oftherapeutic control in 10 patients with congenital adrenal hyperplasia. figure. Six patients were undertreated while on hydrocortisone. The individual patient scores suggested an increased tendency to overtreatment with dexamethasone, particularly when the dexamethasone dose was given in the evening and as a split daily dose. No one dose regimen appeared to result in adequate treatment.
The long term use of the single morning dexamethasone dose required a reduction in the total daily dose (to <10 ,tg/kg/day) in five patients and an increase in the dose in one patient before adequate therapeutic control was achieved. All patients reported an increased appetite during this period of stabilisation, and four gained an abnormal amount of weight. An additional patient developed skin striae and mild hirsutism. The final dose requirement of dexamethasone ranged from 0-2-0-75 mg/day; nine patients needed <05 mg/day to ensure adequate control.
Discussion
Dexamethasone is a synthetic glucocorticoid whose increased potency and longer half life offer the advantages of superior compliance and regulation of menses in older adolescent and adult women with congenital adrenal hyperplasia. Possible growth inhibiting effects are not relevant at this age. Doses which range between 0 25-0-75 mg/day are usually adequate.'-3 In this study, 10 [tg/kg/day of dexamethasone produced a dose range of 0 35-0-8 mg/day. When dexamethasone was started at this dose, given initially in the morning, there was no significant improvement in therapeutic control. There was also a considerable patient idiosyncracy. More patients appeared to be overtreated, particularly when the dexamethasone was given in the evening (either as a single or split dose). A cumulative effect of the steroid may have been achieved by this stage of the study. The 
